Australia is experiencing a surge in M&A as cashed-up private equity funds take advantage of high levels of liquidity in debt markets and volatility in the sharemarket to bid for companies in the healthcare, biotechnology and energy sectors.

Investment bankers at the top firms are as busy as they have been for several years as domestic and international private equity firms, including several from China, target companies with track records of delivering subpar returns.